Check4Cancer receives a nomination in the 2021 Laing Buisson Healthcare Awards

Check4Cancer is delighted to announce that ‘MyCancerRisk’, an online cancer risk assessment tool developed by Check4Cancer has been chosen by the Laing Buisson judges as a finalist in the ‘Innovation in Health Tech’ category for this year’s Laing Buisson Awards.  

The prestigious Laing Buisson Awards celebrate industry excellence at every level of healthcare, and they received a record-breaking number of nominations for the 2021 awards in every single category, with 490 entries in total.

Professor Gordon Wishart, founder and CEO of Check4Cancer comments; ‘’I developed the MyCancerRisk programme to identify those men and women at ‘higher risk’ of six common cancers so that they can undergo personalised cancer screening and education about how to reduce their risk. There is now growing evidence that by targeting screening to those at ‘higher’ risk, a greater proportion of cancers can be detected, and more aggressive cancers can be diagnosed at an earlier stage’’.

Since founding Check4Cancer, Professor Wishart has disrupted the way that UK private cancer diagnostic and screening services are delivered by close collaboration with insured and corporate sectors. He is the former Director of the Cambridge Breast Unit and current Visiting Professor of Cancer Surgery at Anglia Ruskin University, with a strong track record in clinical research and modernisation of cancer services. In 2010 Professor Wishart led a team of scientists that developed the PREDICT breast cancer survival model, used worldwide (www.predict.nhs.uk).

The Laing Buisson Healthcare Awards ceremony will take place on the 18th November at Park Plaza Westminster Bridge, London. Click here to find out more.

For more information on MyCancerRisk, please click here.